Viking Therapeutics reported positive results from its VK2735 maintenance trial in obesity, showing significant weight loss and good tolerability with less frequent dosing. The drug demonstrated competitive or better efficacy compared to Eli Lilly’s tirzepatide and retatrutide, with expectations for improved tolerability in phase 3 trials. Despite a temporary share dip due to a $500 million equity and convertible note offering, this funding supports advancing the pipeline. Viking targets pivotal phase 3 data in 2027 and a commercial launch in 2028, followed by an oral version in 2029.
Viking Therapeutics' recent developments in weight loss maintenance provide context for readers. For those tracking health-sector stocks, 49 of 100 priced US health stocks on Pluang rose and 49 fell today. Notable movers include HIMS at USD 28.65 with a -2.62% change, BNGO at USD 1.70 with a +2.41% change, and ADMA at USD 9.60 with a +2.35% change, as of Sep 28, 2026 22:21 WIB.
Vertex Pharmaceuticals reported a 12% revenue increase to $3.33 billion in Q2, driven by its dominant cystic fibrosis treatments. UBS raised its price target from $585 to $615, reflecting confidence in Vertex's strong financials and growth potential....
Accenture's stock surged 37.6% recently, driven by rising demand for AI services and new AI-focused offerings. The company outpaced industry growth and secured 100 new clients for advanced AI projects in one quarter. An analyst raised the price targe...
SpaceX, trading near $148 per share with a market cap of about $1.95 trillion, is preparing for Starship's first orbital mission and the deployment of its first operational Starlink V3 satellites. This milestone is key for expanding Starlink's global...
Monarch Casino & Resort received a reiterated Buy rating due to strong EBITDA and free cash flow from its Atlantis and Black Hawk properties. Analyst Pedro Goulart highlights a 20% upside target of $147 per share, supported by Reno's tourism momentum...
Johnson & Johnson is poised for growth with a strong oncology and immunology pipeline, including promising drugs like CARVYKTI and TREMFYA showing significant progress. The company reported a 56% stock rally over the past year and raised earnings gui...
